Interindividual variability in drug response is a major clinical problem. Polymedication and
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …

▪ Abstract CYP2C9 is a major cytochrome P450 enzyme that is involved in the metabolic
clearance of a wide variety of therapeutic agents, including nonsteroidal antiinflammatories …

Objective Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide
greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from …

Summary Background 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) has a long half-life of 5–
10 years in human beings as a result of its high lipophilicity, and little or no metabolism. We …

Phenotyping for drug metabolizing enzymes and transporters is used to assess
quantitatively the effect of an intervention (eg, drug therapy, diet) or a condition (eg, genetic …

Abstract Background and Objectives Two phase I drug interaction studies were performed
with oral enzalutamide, which is approved for the treatment of metastatic castration-resistant …

The suitability of the capillary dried blood spot (DBS) sampling method was assessed for
simultaneous phenotyping of cytochrome P450 (CYP) enzymes and P‐glycoprotein (P‐gp) …

Herbal medicines are often used in combination with conventional drugs, and this may give
rise to the potential of harmful herb-drug interactions. This paper updates our knowledge on …

Drugs are administered to patients with the intention of achieving an expected therapeutic
response. Yet drug therapy remains a medical art because of the wide variation in individual …

Objective: The effect of lopinavir/ritonavir (LPV/r) administration on cytochrome P450 (CYP)
enzyme activity was quantified using a phenotyping biomarker cocktail. Changes in …